A 48-year-old woman with rheumatoid arthritis (RA) and a 10-year history of well-controlled hypertension on amlodipine presents with moderate joint pain and swelling. She requires a long-acting NSAID for disease-modifying therapy adjunct. Which NSAID is the drug of choice for chronic RA management with the most favourable cardiovascular and renal safety profile?

Explanation

## NSAIDs in Rheumatoid Arthritis: Cardiovascular & Renal Safety Profile **Key Point:** Among the NSAIDs listed, **Naproxen** has the most favourable cardiovascular safety profile for chronic use. Multiple large-scale studies (including the PRECISION trial and meta-analyses by Bhala et al., Lancet 2013) consistently show that naproxen carries the lowest cardiovascular thrombotic risk among traditional NSAIDs, largely because its twice-daily dosing provides near-complete, sustained platelet COX-1 inhibition — mimicking low-dose aspirin's antiplatelet effect. **High-Yield:** The cardiovascular safety hierarchy among NSAIDs, as established by landmark trials and endorsed by Harrison's Principles of Internal Medicine (21e, Ch. 297) and ACR guidelines, places **naproxen** at the most favourable end of the CV risk spectrum. Ibuprofen and diclofenac carry intermediate-to-high CV risk; indomethacin carries the highest renal and CV risk among traditional NSAIDs. Meloxicam, while preferentially COX-2 selective (~10:1 ratio), does NOT have superior cardiovascular outcome data compared to naproxen and is not classified as a "selective COX-2 inhibitor (coxib)" in standard Indian pharmacology texts (KD Tripathi 8e, Ch. 12). **Clinical Pearl:** In a patient with pre-existing hypertension, naproxen is the preferred long-acting NSAID because: 1. Its sustained COX-1 inhibition reduces prothrombotic risk. 2. It is a long-acting NSAID (half-life ~12–17 hours), suitable for twice-daily dosing in chronic RA. 3. Cardiovascular outcome data from the PRECISION trial (2016) confirmed naproxen's non-inferiority or superiority over celecoxib and ibuprofen for CV events. ## NSAID Cardiovascular & Renal Safety Comparison | NSAID | Half-life | CV Risk | Renal Risk | RA Suitability | |-------|-----------|---------|------------|----------------| | **Naproxen** | 12–17 h | **Lowest** | Moderate | **Preferred (CV-safe)** | | Meloxicam | 15–20 h | Low–Moderate | Moderate | Alternative | | Ibuprofen | 2–4 h | Moderate | Moderate | Short-acting; less preferred | | Indomethacin | 4–5 h | Moderate–High | **Highest** | Not preferred in chronic use | **Why not Meloxicam?** While meloxicam has preferential COX-2 selectivity and good GI tolerability, it does NOT have the robust cardiovascular outcome data that naproxen does. KD Tripathi (8e) and Harrison (21e) do not designate meloxicam as the cardiovascular drug of choice among NSAIDs. The PRECISION trial specifically validated naproxen's CV safety advantage. **Mnemonic:** **NAP**roxen = **N**eutrally **A**ntiplatelet, **P**referred for CV-safe chronic NSAID therapy. [cite: KD Tripathi 8e Ch 12; Harrison 21e Ch 297; PRECISION Trial NEJM 2016; Bhala et al. Lancet 2013]